<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dextran: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dextran: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dextran: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9339" href="/d/html/9339.html" rel="external">see "Dextran: Drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F158641"><span class="drugH1">Brand Names: US</span>
<ul>
<li>LMD in D5W;</li>
<li>LMD in NaCl</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866561"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>LMD in D5W;</li>
<li>LMD in NaCl</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1052075"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Plasma Volume Expander</span></li></ul></div>
<div class="block dop drugH1Div" id="F158663"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose and infusion rate are dependent upon the patient's fluid status and must be individualized.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c6095b34-5d5b-4502-83df-4e318fb8c194">Shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Shock: Note:</b> Crystalloids are recommended as the initial fluid of choice in the resuscitation of severe sepsis and septic shock, not colloids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28509730','lexi-content-ref-23353941','lexi-content-ref-28098591']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28509730','lexi-content-ref-23353941','lexi-content-ref-28098591'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Initial: IV Bolus: 20 mL/kg over at least 5 minutes; repeat as needed based on response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28509730','lexi-content-ref-23353941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28509730','lexi-content-ref-23353941'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3580eebd-40a6-426b-b15a-00c1e9547c06">Volume expansion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Volume expansion (nonshock like conditions):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants: IV: Infuse 5 mL/kg as rapidly as necessary; maximum daily dose: 20 mL/kg/<b>day</b> for first 24 hours, then 10 mL/kg/<b>day</b> thereafter; therapy should not be continued beyond 5 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents &lt;50 kg: IV: Infuse 10 mL/kg as rapidly as necessary; maximum daily dose: 20 mL/kg/<b>day</b> for first 24 hours, then 10 mL/kg/<b>day</b> thereafter; therapy should not be continued beyond 5 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥50 kg: IV: Infuse 500 to 1,000 mL (~10 mL/kg) as rapidly as necessary; maximum daily dose: 20 mL/kg/<b>day</b> for first 24 hours, then 10 mL/kg/<b>day</b> thereafter; therapy should not be continued beyond 5 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d2b52879-d4d8-4967-9cb7-d40f64050af0">Pump prime</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pump prime:</b>
<b>Note:</b> Dose will vary with the volume of the pump oxygenator; doses usually added to the perfusion circuit.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: IV: 5 mL/kg; usual maximum total dose: 20 mL/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Children: IV: 10 mL/kg; usual maximum total dose: 20 mL/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IV: 10 to 20 mL/kg; usual maximum total dose: 20 mL/kg/<b>day</b>.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51109181"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Use with extreme caution.</p></div>
<div class="block dohp drugH1Div" id="F51109182"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Use with extreme caution.</p></div>
<div class="block doa drugH1Div" id="F158644"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9339" href="/d/html/9339.html" rel="external">see "Dextran: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c7f20b5-25e0-4d23-95af-0fcff0353202">Volume expansion/shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Volume expansion/shock:</b>
<b>Note:</b> Crystalloids (eg, sodium chloride or balanced solutions) are recommended as the initial fluid of choice in the resuscitation of sepsis and septic shock (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34605781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34605781'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b>
<i>Dextran 40:</i> Infuse 500 to 1,000 mL (~10 mL/<b>kg</b>) as rapidly as possible (maximum: 20 mL/<b>kg/day</b> for first 24 hours; 10 mL/<b>kg/day</b> thereafter); therapy should not be continued beyond 5 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d2b52879-d4d8-4967-9cb7-d40f64050af0">Pump prime</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pump prime: </b>
<i>Dextran 40:</i> Varies with the volume of the pump oxygenator; generally, the solution is added in a dose of 10 to 20 mL/kg (or 1 to 2 g/kg); usual maximum total dose: 20 mL/kg (or 2 g/kg)</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992042"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use with extreme caution.</p></div>
<div class="block doha drugH1Div" id="F50989278"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use with extreme caution.</p></div>
<div class="block adr drugH1Div" id="F158620"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Chest tightness, hypotension</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Prolonged bleeding time (dose-related), wound hemorrhage (dose-related), wound hematoma (dose-related)</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Abnormal liver function tests</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylactoid reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Acute renal failure</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Pulmonary edema (dose-related), wheezing</p></div>
<div class="block coi drugH1Div" id="F158632"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to dextran or any component of the formulation; marked hemostatic defects (eg, thrombocytopenia, hypofibrinogenemia) of all types including those caused by medications (eg, heparin, warfarin); marked cardiac decompensation; renal disease with severe oliguria or anuria </p></div>
<div class="block war drugH1Div" id="F158617"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Fluid overload: Administration may cause fluid overload; use with caution in patients at risk from overexpansion of blood volume (eg, very young, elderly patients, or those with heart failure).</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hematologic: Large volumes of dextran (doses &gt;1000 mL) may cause reduction in hemoglobin concentration and excessive dilution of plasma proteins due to hemodilution; transient prolongation of bleeding time or an increase in bleeding tendency may occur with large volumes; use caution to prevent a decrease in hematocrit &lt;30%.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hypersensitivity: Severe and fatal anaphylactoid reactions have been reported; discontinue use immediately with signs of hypersensitivity and administer appropriate therapy.   </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal failure: Has been reported with use; fluid status including urine output should be monitored closely.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Heart failure: Use with caution in heart failure patients; monitor closely for fluid overload.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hemorrhage: Use with caution in patients with active hemorrhage;. may increase the risk of more bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal impairment: Use with caution in patients with renal impairment; fluid status including urine output should be monitored closely. Excessive dosing may precipitate renal failure in patients with advanced renal disease. Use in severe oliguria or anuria is contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Thrombocytopenia: Use with caution in patients with thrombocytopenia; doses &gt;1000 mL may interfere with platelet function and transiently prolong bleeding time. Observe for bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Appropriate use: Not a substitute for blood or blood components.</p></div>
<div class="block foc drugH1Div" id="F158627"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LMD in D5W: 10% Dextran 40 (500 mL) [latex free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LMD in NaCl: 10% Dextran 40 (500 mL) [latex free]</p></div>
<div class="block geq drugH1Div" id="F158613"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323102"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (LMD in D5W Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10-5% (per mL): $0.09</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (LMD in NaCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10-0.9% (per mL): $0.10</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866562"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LMD in D5W: 10% Dextran 40 (500 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LMD in NaCl: 10% Dextran 40 (500 mL)</p></div>
<div class="block admp drugH1Div" id="F52612519"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Do not use if crystalline precipitate forms. For IV infusion only (use an infusion pump or pressure infusion); administer through a filter. For volume expansion/shock, may infuse initial volume as rapidly as possible. <b>Monitor closely for anaphylactic reaction; have epinephrine and resuscitative equipment available</b>.</p></div>
<div class="block adm drugH1Div" id="F158629"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Do not use if crystalline precipitate forms. For IV infusion only (use an infusion pump or pressure infusion); administer through a filter. For volume expansion/shock, may infuse initial volume as rapidly as possible. <b>Monitor closely for anaphylactic reaction; have epinephrine and resuscitative equipment available.</b></p></div>
<div class="block sts drugH1Div" id="F158637"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); do not freeze. Do not use if crystalline precipitate forms. Discard partially used containers. </p></div>
<div class="block usep drugH1Div" id="F53566451"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjunctive treatment of shock or impending shock due to trauma (eg, burns, hemorrhage, surgery, surgical complications), a priming fluid in pump oxygenators during extracorporeal circulation, and for venous thrombosis and pulmonary embolism prophylaxis in patients undergoing surgery associated with a high incidence of thromboembolic complications (eg, hip surgery) (All indications: FDA approved in infants, children, adolescents, and adults)</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> This is not a substitute for blood or plasma; does not have oxygen-carrying capacity. Although surgical embolism prophylaxis is included as an FDA-approved use in the manufacturer's prescribing information, current ACCP guidelines for the prevention of venous thromboembolism in surgical patients do not recommend the use of dextran; consider the use of other anticoagulants (Falck-Ytter 2012; Gould 2012).</p></div>
<div class="block mst drugH1Div" id="F158683"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dextran may be confused with Dexedrine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299161"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F1076314"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abciximab: Dextran may enhance the anticoagulant effect of Abciximab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arbekacin: Dextran may enhance the nephrotoxic effect of Arbekacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Dextran may enhance the anticoagulant effect of Desirudin. More specifically, dextran may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with dextran prior to desirudin initiation when possible.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F14446431"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block mopp drugH1Div" id="F53566410"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs, signs of allergic/anaphylactoid reaction; coagulation parameters, hemoglobin, hematocrit, acid-base balance, electrolytes, serum protein, signs of circulatory overload (ie, heart rate, blood pressure, central venous pressure, hematocrit), renal function, urine output; urine specific gravity; platelets</p></div>
<div class="block pha drugH1Div" id="F158616"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Produces plasma volume expansion by virtue of its highly colloidal starch structure.</p></div>
<div class="block phk drugH1Div" id="F158631"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Plasma expanding effect lasts 3-4 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~75%) within 24 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F158634"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Praedex | Promit</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dextran 40 n/sal | Dextran 70 n/sal | Promit | Rheomacrodex 10% glucose | Rheomacrodex saline</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Gentran 70 | Promiten</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Haemodex</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Rheodextran v glukozovem roztoku | Rheodxtran ve fyziologickem roztoku | Tensiton</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Rescueflow | Thomaedex | Thomaedex 40</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dextran 40000 | Dextran 70000 | Macrodex | Rheomacrodex</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bas dextran salino | Macrodex salino | Rheomacrodex salino</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dextrafusin | Dextran-40 na cl | Dextran-70 na cl | Dextril-40 | Dextril-70 | Macrodex leiras | Macrodex+nacl | Promiten | Rescueflow | Rheomacdx+nacl lei | Rheomacrodex+nacl</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dextran B Braun | Promit</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Macrodex saline | Rescueflow | Rheomacrodex | Rheomacrodx</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Fluidex | Macrodex | Macrodex nacl | Promit | Rheomacrodex nacl</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Microspan-40 n.s. | Rallidex in normal saline</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Eudextran | Plander | Plander r | Sol Destrano</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dextran 40 aventis | Dextran 40 kobayashi | Dextran mitsubishi | Dextran terumo | Dextseran d40 | Rheomacrodex kobayashi</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dextran 40 | Inno.n dextran 40 | Jw dextran 40</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Dextran 40 in Sodium Chloride | Dextran 70 in Dextrose</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Haemodex | Macrodex | Reohem | Rheomacrodex | Rheopoliglucin | Tensiton</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dextran 40000 | Dextran 70000 | Haemodex | Reohem | Rheomacrodex | Rheopoliglucin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Onkovertin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Promiten | Rescueflow | Rheomacrodex med natriumklorid</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Onkovertin 70</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Plasmax</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dekstran 70 000 | Promit</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dextran 60 escom | Hemostabil | Neorondex | Polyglucin | Polyglukin | Reopoliglucin | Retinol palmitat | Rheodex 40 | Rheodex 60 | Rheomacrodex | Rheopoliglucin | Rheopoliglukin | Rheopolydex | Rheopolyglukin | Rheopolyglukin 40</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Dextran 70 + natrium | Promiten | Rheomacrodex med natriumklorid</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Onkovertin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Hemodex | Soludeks 40 | Soludeks 70</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Rheodextran v glukozovem | Rheodextran ve fysiologickem | Tensiton</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dekstran | Dekstran 70 | Macrodex | Pf dekstran 40 | Rheomacrodex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Laevodex | Longasteril</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Polyglucin | Rheopoliglucin | Tensiton</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Macrodex | Promit | Rheomacrodex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  10% LMD in 5% Dextrose, 10% LMD in 0.9% Sodium Chloride (dextran 40) [prescribing information]. Lake Forest, IL: Hospira Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28509730">
<a name="28509730"></a>Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. <i>Crit Care Med</i>. 2017;45(6):1061-1093.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextran-pediatric-drug-information/abstract-text/28509730/pubmed" id="28509730" target="_blank">28509730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23353941">
<a name="23353941"></a>Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. <i>Crit Care Med</i>. 2013;41(2):580-637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextran-pediatric-drug-information/abstract-text/23353941/pubmed" id="23353941" target="_blank">23353941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextran-pediatric-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315265">
<a name="22315265"></a>Falck-Ytter Y, Francis CW, Johanson NA, et al; American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 Suppl):e278-e325S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextran-pediatric-drug-information/abstract-text/22315265/pubmed" id="22315265" target="_blank">22315265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315263">
<a name="22315263"></a>Gould MK, Garcia DA, Wren SM, et al; American College of Chest Physicians. Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published correction appears in <i>Chest</i>. 2012;141(5):1369]. <i>Chest</i>. 2012;141(2 Suppl):e227S-e77S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextran-pediatric-drug-information/abstract-text/22315263/pubmed" id="22315263" target="_blank">22315263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20953964">
<a name="20953964"></a>Niemi TT, Miyashita R, and Yamakage M, “Colloid Solutions: A Clinical Update,” <i>J Anesth</i>, 2010, 24(6):913-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextran-pediatric-drug-information/abstract-text/20953964/pubmed" id="20953964" target="_blank">20953964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28098591">
<a name="28098591"></a>Rhodes A, Evans LE, Alhazzani W, et al; Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. <i>Crit Care Med.</i> 2017;45(3):486-552. doi:10.1097/CCM.0000000000002255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextran-pediatric-drug-information/abstract-text/28098591/pubmed" id="28098591" target="_blank">28098591</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13217 Version 119.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
